With randomised controlled trials, the researchers tested the effects of three main reasons – misperception of providers, financial incentives and ORS stock – for under prescription of ORS. While prescribing a lucrative treatment option for financial incentives was perceived to be a barrier (5%), the results of the study suggested that eliminating the incentive (by informing the provider that the patient would purchase medicines from a different location), had no effect on prescription of ORS. When asked about the interventions that the researchers suggest to tackle the problem of under prescription of ORS, Prof.